drugset / Trial / NCT04453397

Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma

NCT04453397 ↗

Expanded access No longer available TeneoOne Inc.

Summary

This is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple myeloma (MM) who is not a candidate for treatment regimens known to provide clinical benefit in MM.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Etentamig Monoclonal antibody — —

Indications